Scarica l'app Stockscreener
68.17
0.81%
-0.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$68.73
Aprire:
$68.61
Volume 24 ore:
2.37M
Relative Volume:
1.14
Capitalizzazione di mercato:
$13.56B
Reddito:
$4.41B
Utile/perdita netta:
$21.27M
Rapporto P/E:
213.03
EPS:
0.32
Flusso di cassa netto:
$288.81M
1 W Prestazione:
+0.92%
1M Prestazione:
+4.38%
6M Prestazione:
-1.96%
1 anno Prestazione:
+15.50%
Intervallo 1D:
$68.00
$69.10
Intervallo di 1 settimana:
$66.83
$71.50
Portata 52W:
$53.56
$83.95
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
68.17 | 13.56B | 4.41B | 21.27M | 288.81M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus
Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha
FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus
FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada
FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus
Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus
Alopecia Areata Market Expected to Experience Major Growth - openPR.com
QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance
Incyte stock rating reiterated by Oppenheimer on promising cancer drug data - Investing.com Canada
Jefferies raises Incyte stock price target on promising drug data By Investing.com - Investing.com Canada
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses - Benzinga
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Yahoo Finance
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies raises Incyte stock price target on promising drug data - Investing.com
Incyte (INCY) Receives Upgrade Amid Promising Drug Data | INCY Stock News - GuruFocus
Incyte stock rating upgraded by Stifel on promising blood disorder drug - Investing.com
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 - BioSpace
Incyte (INCY) Reports Promising Results for Novel Antibody in My - GuruFocus
Incyte (INCY) Receives Upgrade to Buy with $107 Price Target | INCY Stock News - GuruFocus
Incyte (INCY) Reports Promising Results for Novel Antibody in Myeloproliferative Neoplasms | INCY Stock News - GuruFocus
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches - Insider Monkey
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Quantisnow
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR- - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma – Company AnnouncementFT.com - Financial Times
Incyte’s SWOT analysis: stock faces patent cliff as pipeline progress mixed - Investing.com
Specialised Therapeutics announces expanded partnership with Incyte - Yahoo Finance
Specialised Therapeutics Expands Partnership with Incyte to Incl - GuruFocus
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - BioSpace
Incyte (INCY) Reports Promising Results from Phase 3 Retifanlimab Trial | INCY Stock News - GuruFocus
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with - GuruFocus
) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - Business Wire
Specialised Therapeutics expands oncology portfolio with Incyte deal - Investing.com
Incyte (INCY) Expands Partnership with Specialised Therapeutics in Asia-Pacific | INCY Stock News - GuruFocus
Incyte Doubles Down in Asia-Pacific: New Partnership Brings Breakthrough Cancer Treatments to High-Need Markets - Stock Titan
Incyte Corporation (INCY) Announces Amendments to Stock Incentiv - GuruFocus
Incyte stockholders endorse plan amendments and board members By Investing.com - Investing.com Canada
Incyte stockholders endorse plan amendments and board members - Investing.com
Incyte stock holds steady as UBS maintains neutral rating - Investing.com
Incyte to Showcase Groundbreaking Hematology/Oncology Data at EHA 2025 - MSN
Incyte at Goldman Sachs Conference: Growth Beyond Jakafi - Investing.com
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
Morgan Stanley Maintains Hold Rating on Incyte (INCY) Stock - Insider Monkey
Stifel maintains hold rating on Incyte stock, keeps $75 price target - Investing.com
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Incyte Corp Azioni (INCY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Jun 03 '25 |
Sale |
68.00 |
1,795 |
122,060 |
26,504 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):